Thomas Scharnitz - Bristol Myers Squibb

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

51101 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Static Physician Global Assessment (spga) in Two Phase 3 Trials

Jeffrey M. Sobell, Boni Elewski, Seong Jun Seo, Subhashis Banerjee,Eugene Balagula,Thomas Scharnitz,Kim Hoyt,Paul Yamauchi,Miriam Bettencourt,Michael C. Cameron, Mark Lebwohl

Journal of the American Academy of Dermatologyno. 3 (2024): AB31

引用0浏览0引用

51109 Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data

Andrew Blauvelt,Howard Sofen, Jo Lambert, Joseph F. Merola, Mark Lebwohl,Kim Hoyt,Renata M. Kisa, Subhashis Banerjee,Thomas Scharnitz,Jeffrey J. Crowley

Journal of the American Academy of Dermatologyno. 3 (2024): AB37

引用0浏览0引用

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-Year Results from the POETYK PSO Program

Mark Lebwohl,Richard B. Warren,Shinichi Imafuku,Jerry Bagel,April W. Armstrong,Thierry Passeron,Subhashis Banerjee,Renata M. Kisa,Eleni Vritzali,Matthew J. Colombo,Thomas Scharnitz,Kim Hoyt,Diamant Thaçi,Andrew Blauvelt

SKIN The Journal of Cutaneous Medicineno. 2 (2024)

引用0浏览0引用

51214 Deucravacitinib Efficacy in Palmoplantar and Fingernail Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA) in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Boni Elewski, Jo Lambert, Joseph F. Merola, Mark Lebwohl,Kim Hoyt,Renata M. Kisa, Subhashis Banerjee,Thomas Scharnitz, Jennifer Cather

Journal of the American Academy of Dermatologyno. 3 (2024): AB179

引用0浏览0引用

43887 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Melinda Gooderham,Lynda Spelman,Shinichi Imafuku,Marco Romanelli,Joseph F. Merola,April W. Armstrong,Elizabeth Colston,Subhashis Banerjee,Thomas Scharnitz,Andrew Blauvelt

Skinno. 4 (2023): s219-s219

引用0浏览0引用

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Mark Lebwohl,Bruce Strober,Thomas Scharnitz,Misti Linaberry,Kim Hoyt,Subhashis Banerjee,Renata M. Kisa,George M. Martin

Skin（2023）

引用0浏览0引用

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)

April W. Armstrong,Mark Lebwohl,Jerry Bagel,Todd Schlesinger,Subhashis Banerjee,Renata M. Kisa,Thomas Scharnitz,Kim Hoyt,Bruce Strober

SKIN The Journal of Cutaneous Medicine（2023）

引用0浏览0引用

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)

Jeffrey M. Sobell,Boni E. Elewski,Subhashis Banerjee,Eugene Balagula,Thomas Scharnitz,Victoria Berger,Kim Hoyt,Paul S. Yamauchi, Miriam S. Bettencourt,Michael C. Cameron,Mark Lebwohl

Skinno. 6 (2023): s238-s238

引用0浏览0引用

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program

Richard B. Warren,April W. Armstrong,Shinichi Imafuku,Carle Paul,Leon Kircik,Elizabeth Colston,Thomas Scharnitz,Tao Wang,Subhashis Banerjee,Bruce Strober

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2023）

引用0浏览0引用

Melinda Gooderham,Lynda Spelman,Shinichi Imafuku,Marco Romanelli,Joseph F. Merola,April W. Armstrong,Elizabeth Colston,Subhashis Banerjee,Thomas Scharnitz,Andrew Blauvelt

Journal of the American Academy of Dermatologyno. 3 (2023): AB35-AB35

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn